drug

PRT12396

1 story · latest Aug 11, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Prelude Therapeutics Incorporated

Timeline

Prelude reports Q2 2026 results, plans Phase 1 start for KAT6A degrader PRT13722

Aug 11Quarterly updatePrelude Therapeutics Incorporated PRT12396

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.